General self-efficacy scale (GSE). Outcomes measurement tool: attitudes & feelings - self-efficacy.

The ten-item General Self-Efficacy Scale is correlated to emotion, optimism and work satisfaction. Negative coefficients were found for depression, stress, health complaints, burnout, and anxiety

STUDI REGIM ALIRAN FLUIDA DAN PENENTUAN HEAD LOSS AKIBAT GESEKAN PADA INSTALASI PERPIPAAN

Instalasi perpipaan dalam industry merupakan sistem keteknikan memegang perananan penting yang berfungsi untuk mengalirkan  air, minyak dan gas dari satu titik ke titik lain melalui semua komponen yang tercakup didalamnya. Sistem perpipaan terdiri dari pipa lurus, sambungan-sambungan, belokan katup-katup dan peralatan-peralatan instrumentasi yang harus bekerja secara optimal. Regim aliran fluida di dalam berbagai komponen perpipaan memberikan pengaruh terhadap aliran teristimewa pada dua parameter penting yaitu koefesien gesek dan kehilangan head. Tujuan penelitian ini adalah memantau sifat pergerakan fluida dalam rezim laminar dan turbulen dan menentukan nilai head loss sebagai fungsi debit dalam rezim laminar dan turbulen. Penelitian dilakukan pada pipa lurus berdiamater 4 inci dengan panjang total 10 meter, diameter 4 inci dengan satu belokan 90o. Penentuan hubungan kerugian head terhadap debit dilakukan melalui simulasi hidrodinamika, dimana kecepatan aliran divariasi dari 0,02 - 0,1 m/s, sesuai dengan debit Q = 10-52 liter/menit. Variasi kecepatan ini melewati regim aliran laminar dan turbulen yang diukur pada 4 penampang pada pipa lurus dan elbow. Hasil yang diperoleh menunjukan bahwa profil aliran pada setiap penampang berbeda-bada untuk nilai debit Q yang sama. Pada setiap penampang dengan variasi nilai debit Q, karakter nilai kerugian head meningkat dengan meningkatnya debit aliran Q dengan nilai berbeda pada setiap penampang, namun trend perubahannya mirip. Kondisi laminar terjadi pada Q <34 lit/menit dengan kerugian head hdl < 0,74x10-3 m,  transisi terjadi pada Q=34-36 lit/menit, dengan hdl = (0,74 -0,68)x10-3 m dan turbulen sepenuhnya pada Q>36 lit/menit dengan hdl > 0,74x10-3 m. Hal ini menujukan bahwa pada elbow atau belokan, aliran akan menjadi turbulen walaupun pada kecepatan yang rendah

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

Radium-223 dichloride (radium-223) mimics calcium and emits high-energy, short-range alpha-particles resulting in an antitumor effect on bone metastases. This open-label, phase IIa nonrandomized study investigated safety and short-term efficacy of radium-223 in breast cancer patients with bone-dominant disease. Twenty-three advanced breast cancer patients with progressive bone-dominant disease, and no longer candidates for further endocrine therapy, were to receive radium-223 (50 kBq/kg IV) every 4 weeks for 4 cycles. The coprimary end points were change in urinary N-telopeptide of type 1 (uNTX-1) and serum bone alkaline phosphatase (bALP) after 16 weeks of treatment. Exploratory end points included sequential 18F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET/CT) to assess metabolic changes in osteoblastic bone metastases. Safety data were collected for all patients. Radium-223 significantly reduced uNTX-1 and bALP from baseline to end of treatment. Median uNTX-1 change was −10.1 nmol bone collagen equivalents/mmol creatinine (−32.8 %; P = 0.0124); median bALP change was −16.7 ng/mL (−42.0 %; P = 0.0045). Twenty of twenty-three patients had FDG PET/CT identifying 155 hypermetabolic osteoblastic bone lesions at baseline: 50 lesions showed metabolic decrease (≥25 % reduction of maximum standardized uptake value from baseline) after 2 radium-223 injections [32.3 % metabolic response rate (mRR) at week 9], persisting after the treatment period (41.5 % mRR at week 17). Radium-223 was safe and well tolerated. Radium-223 targets areas of increased bone metabolism and shows biological activity in advanced breast cancer patients with bone-dominant disease

Model Pendampingan Bisnis Mahasiswa Penerima Hibah PKM-K/PMW melalui Teknik Coaching sebagai Upaya Akselerasi Pertumbuhan Bisnis Mahasiswa

Untuk mencetak lulusan yang berorientasi pencetak lapangan kerja, maka Kemendikbud meluncurkan program mahasiswa wirausaha, PKM-K dan PMW. Salah satu masalah dalam program tersebut adalah ketidakefektifan pendampingan bisnis oleh dosen. Akibatnya bisnis yang dijalankan mahasiswa tidak berkembang, dan karakter entrepreneurships juga tidak tumbuh. Tujuan utama dalam jangka panjang penelitian ini adalah akselerasi penumbuhan bisnis mahasiswa. Dalam penelitian ini, tujuan yag hendak dicapai adalah pengembangan model model pendampingan bisnis mahasiswa yang efektif, efisien dan terkurikulum sehingga dapat mempercepat pertumbuhan bisnis. Pengembangan model menghasilkan model pendampingan bisnis mahasiswa yang terdiri atas 2 fase; review, coaching, dan challenge. Model ini efektif dalam merangsang mahasiswa untuk merancang dan melakukan aksi bisnis untuk menumbuhkembangkan bisnisnya

PEMANFAATAN INTERNET SEBAGAI MEDIA PUBLIKASI DAN LITERASI INFORMASI UNTUK MENGEMBANGKAN BAHAN AJAR BAGI GURU KETERAMPILAN SLTP DI KABUPATEN SLEMAN

Tujuan yang hendak dicapai melalui kegiatan PPM dalam bentuk pelatihan pemanfaatan internet sebagai media publikasi dan literasi informasi adalah 1) agar para guru mampu menggunakan internet meliputi browsing, dan download untuk menunjang kegiatan akademik dan literasi informasi; 2) agar guru mampu membuat email dan blog sebagai media publikasi. Peserta pelatihan ini adalah Guru Ketrampilan SLTP di Kabupaten Sleman Yogyakarta berjumlah 24 orang. Pelatihan ini diselenggarakan di Laboratorium Komputer Jurusan PTBB-FT-UNY pada tanggal 22 dan 29 Juli 2010. Materi yang disampaikan adalah pemanfaatan internet secara praktis untuk kebutuhan akademis dalam hal literasi informasi dan publikasi. Materi literasi informasi terdiri dari browsing dan download, sedang materi publikasi terdiri dari email dan blog. Metode yang digunakan adalah ceramah, demonstrasi, praktek dan pembimbingan aplikasi internet. Berdasar hasil pelatihan diketahui bahwa: 1) guru ketrampilan SLTP telah mampu memanfaatkan internet untuk menunjang kegiatan akademik dan literasi informasi dengan melakukan browsing, dan download. Capaian keberhasilan ini sebesar 90% peserta pelatihan mampu melakukan browsing, dan download. 2) guru ketrampilan SLTP telah mempu mengoptimalkan pemanfaatan internet untuk kepentingan publikasi melalui email dan blog. Capaian keberhasilan ini sebesar 75% peserta pelatihan mampu membuat email dan blog. Berdasarkan hasil evaluasi kegiatan melalui kuesioner yang dibagikan kepada peserta pada prinsipnya peserta menyatakan puas dan senang mengikuti pelatihan ini bahkan mengharapkan ada program lanjutan dengan materi sejenis/lanjutan

18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin’s disease: a case report

<p>Abstract</p> <p>Introduction</p> <p>The occurrence of granulomatous disease in the setting of Hodgkin's disease is rare; however, when it occurs it can pose significant clinical and diagnostic challenges for physicians treating these patients.</p> <p>Case presentation</p> <p>We report the case of a 33-year-old Caucasian woman of Mediterranean descent with newly diagnosed ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT) scan-positive, early-stage Hodgkin's disease involving the cervical nodes who, despite having an excellent clinical response to chemotherapy, had a persistent ¹⁸F-FDG PET scan-positive study, which was suggestive of residual or progressive disease. A subsequent biopsy of her post-chemotherapy PET-positive nodes demonstrated sarcoidosis with no evidence of Hodgkin's disease.</p> <p>Conclusion</p> <p>This case highlights the fact that abnormalities observed on posttherapy PET/CT scans in patients with Hodgkin's disease are not always due to residual or progressive disease. An association between Hodgkin's disease and/or its treatment with an increased incidence of granulomatous disease appears to exist. Certain patterns of ¹⁸F-FDG uptake observed on PET/CT scans may suggest other pathologies, such as granulomatous inflammation, and because of the significant differences in prognosis and management, clinicians should maintain a low threshold of confidence for basing their diagnosis on histopathological evaluations when PET/CT results appear to be incongruent with the patient's clinical response.</p

Upaya Sekolah Dalam Meningkatkan Kepercayaan Masyarakat Di SMK Muhammadiyah 1 Weleri Kendal

Student self-confidence has an impact on their motivation in vocational schools (SMK). School marketing is crucial to enhance public trust in SMK. Effective marketing can improve the school's image and reputation. Additionally, the readiness of students for the workforce is vital because prepared students can make a positive contribution to society. The objective of this research is to describe the efforts of the school in enhancing public trust and to identify the factors that hinder or support the level of public trust in SMK Muhammadiyah 1 Weleri Kendal. This research is qualitative in nature, specifically a field research, employing a phenomenological approach by collecting data through observation, interviews, and document studies. The research was conducted at SMK Muhammadiyah 1 Weleri. The research results indicate that the school's efforts to boost public trust involve strengthening AIK values through student councils (LDK/LDPR), orientation programs (MPLS/FORTASI), congregational Dhuha prayers, communal Quran recitation, and obligatory prayers. Additionally, the school fosters community relations with orphan support programs, animal sacrifices, and Albamart. Finally, the school's services are well-received by parents, as assessed through a familial approach. Furthermore, the factors affecting public trust in SMK Muhammadiyah 1 Weleri can be divided into inhibiting and supporting factors. Inhibiting factors include fluctuating student percentages, limited infrastructure, teachers without bachelor's degrees, teachers teaching subjects outside their expertise, suboptimal marketing promotions, and an unfavorable school location. On the other hand, supporting factors comprise affordable school fees, a conducive school location for learning activities, and the availability of a training center building for practical training

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). Patients and methods: This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received ≤1 line of endocrine therapy (ET) but no chemotherapy for ABC. Patients, assigned 2:1, were stratified by the presence/absence of liver/lung metastases and previous ET. Patients received intramuscular fulvestrant (500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1) with oral ribociclib (600 mg/day, 3 weeks on, 1 week off) or placebo. Efficacy analyses were by intention to treat. Safety was assessed in patients receiving ≥1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling). Results: Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (∼60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. Conclusions: This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy

Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.

This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) without prior CDK4 and 6 inhibitor exposure. Patients were divided into two cohorts: treatment naïve (cohort 1) and pretreated (cohort 2). Patients received abemaciclib plus pembrolizumab with (cohort 1) or without (cohort 2) anastrozole over 21-day cycles. The primary objective was safety, and secondary objectives included efficacy and pharmacokinetics (PK). Cohort 1/2 enrolled 26/28 patients, respectively. Neutropenia (30.8/28.6%), AST increase (34.6/17.9%), ALT increase (42.3/10.7%), and diarrhea (3.8/10.7%) were the most frequent grade ≥3 adverse events in cohort 1/2, respectively. A total of two deaths occurred, which investigators attributed to treatment-related adverse events (AEs), both in cohort 1. Higher rates of all grade and grade ≥3 interstitial lung disease (ILD)/pneumonitis were observed compared to previously reported with abemaciclib and pembrolizumab monotherapy. The PK profiles were consistent between cohorts and with previous monotherapy studies. In cohorts 1/2, the overall response rate and disease control rate were 23.1/28.6% and 84.6/82.1%, respectively. Median progression-free survival and overall survivals were 8.9 (95% CI: 3.9-11.1) and 26.3 months (95% CI: 20.0-31.0) for cohort 2; cohort 1 data are immature. Abemaciclib plus pembrolizumab demonstrated antitumor activity, but high rates of ILD/pneumonitis and severe transaminase elevations occurred with/without anastrozole compared to the previous reporting. Benefit/risk analysis does not support further evaluation of this combination in the treatment of HR+, HER2- MBC.We thank the patients and families who participated in this study, caregivers, the study investigators, and their staff, and the JPCE (NCT02779751) clinical trial team. Pembrolizumab was provided by Merck & Co., Inc., Kenilworth, NJ, USA. We thank Anne Chain from the Department of Quantitative Pharmacology & PharmacometricsImmune/Oncology, Merck & Co., Inc., Kenilworth, NJ, USA for her contributions to this work, which included pembrolizumab PK and ADA analysis. This work and medical writing support was funded by Eli Lilly and Company.S